IRONWOOD PHARMACEUTICALS INC

Listed Company

IRWDCIK 0001446847NasdaqAcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$296.15M

Net Income

$24.02M

Total Assets

$396.90M

Equity

$-261.83M

Shares Out

164.61M

Op. Cash Flow

$127.04M

IRWD$3.85+385.01% · past yearDBEQ Basic

Daily closing prices

Business

Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. Its commercial product LINZESS (linaclotide) is a GC-C agonist approved in the U.S., Canada, Europe, Mexico, Japan, and China for IBS-C, CIC, and pediatric functional constipation. The company partners with AbbVie, AstraZeneca, and Astellas for global linaclotide commercialization, and is advancing apraglutide, a GLP-2 analog for short bowel syndrome, through Phase III clinical trials. Revenue is primarily derived from collaborative arrangements and milestone payments related to linaclotide partnerships.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	296	351	443	411	414
Research and development	95	111	116	44	70
Selling, general and administrative	82	144	158	116	111
Restructuring, net	20	3	18	—	−44,000
Total costs and expenses	198	258	1,388	160	181
Income from operations	99	93	−945	250	232
Interest expense and other financing costs	−33	−33	−22	−8	—
Interest and investment income	4	4	19	10	726,000
Other	193,000	640,000	—	—	—
Other income (expense), net	−28	−28	−3	2	−32
Income before income taxes	70	65	−948	252	201
Income tax expense	−46	−64	−84	−77	328
Net income	24	880,000	−1,002	175	528
Net income per share - basic (in dollars per share)	0.15	0.01	−6.45	1.13	3.26
Net income per share - diluted (in dollars per share)	0.15	0.01	−6.45	0.96	3.21
Weighted average shares used in computing net income per share - basic (in shares)	162	159	155	154	162
Weighted average shares used in computing net income per share - diluted (in shares)	163	160	155	186	164

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	215	89	92	656	620
Accounts receivable, net	47	82	129	115	114
Prepaid expenses and other current assets	12	12	12	8	9
Total current assets	274	182	233	781	745
Property and equipment, net	3	4	6	6	8
Operating lease right-of-use assets	9	11	13	14	15
Intangible assets, net	2	3	4	—	—
Deferred tax assets	103	144	212	284	333
Other assets	5	6	4	847,000	1
Total assets	397	351	471	1,101	1,127
Accounts payable	3	2	8	483,000	935,000
Accrued research and development costs	3	7	21	5	16
Accrued expenses and other current liabilities	33	27	44	17	24
Current portion of operating lease liabilities	3	3	3	3	3
Current portion of convertible senior notes	200	—	200	—	117
Total current liabilities	242	39	276	26	162
Convertible senior notes, net of current portion	—	199	198	396	337
Operating lease obligations, net of current portion	10	12	15	17	18
Revolving credit facility	385	385	300	—	—
Other liabilities	22	17	28	10	4
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding	—	—	—	—	—
Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 163,058,316 shares issued and outstanding as of December 31, 2025 and 500,000,000 shares authorized and 160,205,899 shares issued and outstanding as of December 31, 2024	163,000	160,000	156,000	154,000	162,000
Additional paid-in capital	1,413	1,395	1,355	1,349	1,543
Accumulated deficit	−1,674	−1,698	−1,699	−696	−938
Accumulated other comprehensive income (loss)	−1	923,000	−3	—	—
Total stockholders' deficit	−262	−301	−346	652	606
Total liabilities and stockholders' deficit	397	351	471	1,101	1,127

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	2	2	2	1	2
Loss on disposal of property and equipment	89,000	75,000	—	2,000	93,000
Share-based compensation expense	17	30	32	27	22
Non-cash interest expense	2	2	—	—	—
Non-cash lease expense	2	2	—	—	—
Deferred income taxes	41	68	73	66	−333
Accounts receivable, net	35	47	924,000	8	8
Prepaid expenses and other current assets	367,000	89,000	4	3	601,000
Other assets	447,000	−854,000	−319,000	153,000	−57,000
Accounts payable and accrued expenses	6	−20	12	−8	−3
Accrued research and development costs	−4	−15	−6	−11	14
Operating lease liabilities	−2	−2	−2	−2	−2
Other liabilities	4	−10	507,000	11	−1
Net cash provided by operating activities	127	104	183	274	262
Purchases of property and equipment	−34,000	−142,000	−273,000	−136,000	−265,000
Net cash used in investing activities	−34,000	−142,000	−1,026	−136,000	−265,000
Proceeds from exercise of stock options and employee stock purchase plan	216,000	11	6	10	20
Taxes paid related to net share settlement of share-based awards	—	−737,000	—	—	—
Repayment of 2024 Convertible Notes	—	−200	—	−121	—
Proceeds from revolving credit facility	—	150	400	—	—
Costs associated with revolving credit facility	—	−2	−3	—	—
Repayments of revolving credit facility	—	−65	−100	—	—
Net cash provided by (used in) financing activities	216,000	−107	277	−238	−5
Effect of exchange rate changes on cash and cash equivalents	−329,000	−32,000	−53,000	—	—
Net increase (decrease) in cash and cash equivalents	127	−4	−566	36	257
Cash paid for interest	30	33	14	6	7
Cash paid for income taxes	4	8	10	5	3

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is IRONWOOD PHARMACEUTICALS INC's CIK number?

IRONWOOD PHARMACEUTICALS INC's SEC CIK number is 0001446847 (1446847). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find IRONWOOD PHARMACEUTICALS INC's SEC filings?

All of IRONWOOD PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did IRONWOOD PHARMACEUTICALS INC last report earnings?

IRONWOOD PHARMACEUTICALS INC (IRWD) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-056656). This is IRONWOOD PHARMACEUTICALS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is IRONWOOD PHARMACEUTICALS INC's most recent earnings 8-K?

IRONWOOD PHARMACEUTICALS INC's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-056656. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View IRONWOOD PHARMACEUTICALS INC's latest earnings 8-K →
Look up any company's CIK number →